Clinical Trial

ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Carmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, Ana Oaknin

10.1136/ijgc-2022-003370

April 20, 2022

CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer

Jean-Marc Classe, Gwennael Ferron, Lobna Ouldamer, Tristan Gauthier, Sheik Emambux, Laurence Gladieff, Pierre-Francois Dupre, Amélie Anota

10.1136/ijgc-2021-003320

March 23, 2022

Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, Ettore Capoluongo, Maria Paola Costi, Maurizio D'Incalci, Sergio Marchini, Delia Mezzanzanica, Nicola Normanno, Stefania Scala, Stefano Greggi, Francesco Perrone, Sandro Pignata

10.1136/ijgc-2022-003435

March 22, 2022

Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)

Glauco Baiocchi, Carlos Eduardo Mattos Cunha Andrade, Reitan Ribeiro, Renato Moretti-Marques, Audrey Tieko Tsunoda, Vanessa Alvarenga-Bezerra, Andre Lopes, Ronaldo Lúcio Rangel Costa, Lillian Yuri Kumagai, Levon Badiglian-Filho, Carlos Chaves Faloppa, Henrique Mantoan, Louise De Brot, Ricardo Dos Reis, Bruna Tirapelli Goncalves

10.1136/ijgc-2022-003378

March 2, 2022

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Pignata, Lucy Gilbert, Diego Kaen, M Jesús Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof Vulsteke, Kosei Hasegawa, Elena Ioanna Braicu, Xiaohua Wu, Jodi McKenzie, John J Lee, Vicky Makker

10.1136/ijgc-2021-003017

November 19, 2021

PROPER—PRehabilitatiOn Plus Enhanced Recovery after surgery versus enhanced recovery after surgery in gynecologic oncology: a randomized clinical trial

Andre Lopes, Alayne Magalhães Trindade Domingues Yamada, Thais de Campos Cardenas, Jaqueline Nunes de Carvalho, Emília de Azevedo Oliveira, Marina Elisa Ribeiro da Silva, Juliana Fenerich Mauri Andrade, Eduardo de Souza Neto, Lilian Arruda do Rêgo Barros, Ronaldo Lúcio Rangel Costa

10.1136/ijgc-2021-003170

November 8, 2021

A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020

Andreas Obermair, Jim Nicklin, Val Gebski, Sandra C Hayes, Nicholas Graves, Linda Mileshkin, Ming Yin Lin, Phillip Beale, Eva Baxter, Kristy Robledo, Carlos Salomon, George B Hanna, Monika Janda

10.1136/ijgc-2021-003029

November 2, 2021

ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

Joyce Liu, Amit M Oza, Nicoletta Colombo, Ana Oaknin

10.1136/ijgc-2021-003144

October 29, 2021

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Nicoletta Colombo, Jean Sebastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Teresa Perri, Caterina Ricci, Giovanni Scambia, Domenica Lorusso

10.1136/ijgc-2021-002593

October 4, 2021

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, Michelle K Wilson, Amit M Oza, Ana Oaknin, David M O’Malley, Domenica Lorusso, Shannon N Westin, Tamar Safra, Thomas J Herzog, Frederik Marmé, Ramez N Eskander, Kevin K Lin, Danny Shih, Sandra Goble, Nikolay Grechko, Stephanie Hume, Lara Maloney, Iain A McNeish, Rebecca S Kristeleit

10.1136/ijgc-2021-002933

September 30, 2021